BAP1 Mutant Malignant Pleural Mesothelioma (MPM): Outcomes with Chemotherapy, ICPi and PARPi

被引：1
|
作者：
Dudnik, E. [1 ]
Bar, J. [2 ]
Kuznetsov, T. [2 ]
Moskovitz, M. [3 ]
Dudnik, J. [4 ]
Shochat, T. [5 ]
Zer, A. [1 ]
Urban, D. [2 ]
机构：
[1] Rabin Med Ctr, Davidoff Canc Ctr, Thorac Canc Serv, Petah Tiqwa, Israel
[2] Chaim Sheba Med Ctr, Inst Oncol, Ramat Gan, Israel
[3] Rambam Hlth Care Campus, Thorac Canc Serv, Haifa, Israel
[4] Soroka Univ Med Ctr, Inst Canc, Beer Sheva, Israel
[5] Rabin Med Ctr, Stat Consulting Unit, Petah Tiqwa, Israel
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
BAP1; immune check-point inhibitors; poly (ADP-ribose) polymerase inhibitors;
D O I：
10.1016/j.jtho.2019.08.1632
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.06-14
引用
收藏
页码：S760 / S760
页数：1
相关论文
共 50 条
  • [41] BAP1 Loss Portends Improved Prognosis in Malignant Pleural Mesothelioma Due To Frequent Association With Epithelioid Morphology
    McGregor, Stephanie
    Dunning, Ryan
    Hadi, Duraid
    Vigneswaran, Wickii
    Husain, Aliya
    Krausz, Thomas
    MODERN PATHOLOGY, 2015, 28 : 484A - 484A
  • [42] BAP1 Deficiency Inflames the Tumor Immune Microenvironment and Is a Candidate Biomarker for Immunotherapy Response in Malignant Pleural Mesothelioma
    Xu, Duo
    Gao, Yanyun
    Yang, Haitang
    Spils, Marc
    Marti, Thomas M.
    Losmanova, Tereza
    Su, Min
    Wang, Wenxiang
    Zhou, Qinghua
    Dorn, Patrick
    Shu, Yongqian
    Peng, Ren-Wang
    JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (05):
  • [43] Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications
    Forest, Fabien
    Patoir, Arnaud
    Dal Col, Pierre
    Sulaiman, Abdulrazzaq
    Camy, Florian
    Laville, David
    Bayle-Bleuez, Sophie
    Fournel, Pierre
    Habougit, Cyril
    PATHOLOGY, 2018, 50 (06) : 635 - 641
  • [44] Dysphagia in Patients with Malignant Pleural Mesothelioma (MPM)
    Malec, M.
    Desai, A.
    Waxman, I.
    Karrison, T.
    Rose, B.
    Mendoza, A.
    Gadiraju, M.
    Straus, C.
    Churpek, J.
    Kindler, H.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S759 - S760
  • [45] Chemotherapy for malignant pleural mesothelioma (MPM) in the era of pemetrexed: experience in Northern Ireland
    Campbell, L.
    Scullin, P.
    LUNG CANCER, 2009, 63 : S8 - S8
  • [46] A retrospective analysis of second-line chemotherapy for malignant pleural mesothelioma (MPM)
    La Verde, N. M.
    Bramati, A.
    Cinquini, M.
    Tiseo, M.
    Collova, E.
    Michetti, A.
    Lo Dico, M.
    Foliador, A.
    Garassino, M. C.
    Zucaii, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [47] Combined Use of p16 FISH and Bap1 Immunohistochemistry Optimizes Diagnosis of Malignant Pleural Mesothelioma
    McGregor, S. M.
    Minor, A.
    Fitzpatrick, C.
    Husain, A. N.
    Hyjek, E.
    Vigneswaran, W.
    Krausz, T.
    MODERN PATHOLOGY, 2013, 26 : 460A - 460A
  • [48] Malignant pleural mesothelioma (MPM) -: the Italian experience
    Crinó, L
    Benedetti, G
    LUNG CANCER, 2004, 45 : S137 - S138
  • [49] Diagnostic application of BAP1 immunohistochemistry to differentiate pleural mesothelioma from metastatic pleural tumours
    Yoshimura, Masayo
    Kinoshita, Yoshiaki
    Hamasaki, Makoto
    Matsumoto, Shinji
    Hida, Tomoyuki
    Oda, Yoshinao
    Nabeshima, Kazuki
    HISTOPATHOLOGY, 2017, 71 (06) : 1011 - 1014
  • [50] Malignant Pleural Mesothelioma (MPM) Presenting as Hydropneumothorax
    Kuramochi, Masami
    Muraoka, Takuma
    Shinonaga, Mayumi
    Ohtani, Haruo
    Kuraoka, Setsuo
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (07)
12345